Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Amryt Pharma plc stock logo
AMYT
Amryt Pharma
$14.70
+0.1%
$14.64
$6.41
$14.77
$940.21M0.84757,360 shs2.39 million shs
IGC Pharma, Inc. stock logo
IGC
IGC Pharma
$0.36
+9.8%
$0.34
$0.25
$0.48
$30.83M1.48913,992 shs214,616 shs
Organon & Co. stock logo
OGN
Organon & Co.
$9.39
+0.3%
$9.75
$8.01
$23.10
$2.44B0.64.52 million shs3.58 million shs
Silence Therapeutics PLC Sponsored ADR stock logo
SLN
Silence Therapeutics
$5.63
-3.8%
$5.81
$1.97
$20.48
$168.51M1.39209,016 shs37,199 shs
Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Amryt Pharma plc stock logo
AMYT
Amryt Pharma
0.00%0.00%0.00%0.00%0.00%
IGC Pharma, Inc. stock logo
IGC
IGC Pharma
+3.46%+5.28%-2.45%+22.53%-11.45%
Organon & Co. stock logo
OGN
Organon & Co.
+3.31%+7.16%-4.95%+6.00%-53.96%
Silence Therapeutics PLC Sponsored ADR stock logo
SLN
Silence Therapeutics
+4.65%+9.96%-6.85%+45.89%-64.76%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Amryt Pharma plc stock logo
AMYT
Amryt Pharma
N/AN/AN/AN/AN/AN/AN/AN/A
IGC Pharma, Inc. stock logo
IGC
IGC Pharma
1.8206 of 5 stars
3.50.00.00.01.91.70.0
Organon & Co. stock logo
OGN
Organon & Co.
4.7977 of 5 stars
3.32.01.73.73.31.73.1
Silence Therapeutics PLC Sponsored ADR stock logo
SLN
Silence Therapeutics
2.4871 of 5 stars
3.44.00.00.01.01.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Amryt Pharma plc stock logo
AMYT
Amryt Pharma
0.00
N/AN/AN/A
IGC Pharma, Inc. stock logo
IGC
IGC Pharma
3.00
Buy$3.88982.40% Upside
Organon & Co. stock logo
OGN
Organon & Co.
2.50
Moderate Buy$18.0091.80% Upside
Silence Therapeutics PLC Sponsored ADR stock logo
SLN
Silence Therapeutics
2.71
Moderate Buy$33.83500.95% Upside

Current Analyst Ratings Breakdown

Latest IGC, SLN, AMYT, and OGN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/8/2025
Silence Therapeutics PLC Sponsored ADR stock logo
SLN
Silence Therapeutics
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$35.00
6/13/2025
Silence Therapeutics PLC Sponsored ADR stock logo
SLN
Silence Therapeutics
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$35.00
6/13/2025
Silence Therapeutics PLC Sponsored ADR stock logo
SLN
Silence Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$75.00
5/22/2025
Organon & Co. stock logo
OGN
Organon & Co.
BNP Paribas
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
5/15/2025
Organon & Co. stock logo
OGN
Organon & Co.
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$24.00 ➝ $18.00
(Data available from 8/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Amryt Pharma plc stock logo
AMYT
Amryt Pharma
$222.54M4.22$0.98 per share14.98$5.58 per share2.63
IGC Pharma, Inc. stock logo
IGC
IGC Pharma
$1.27M25.58N/AN/A$0.08 per share4.48
Organon & Co. stock logo
OGN
Organon & Co.
$6.28B0.39$5.10 per share1.84$2.82 per share3.33
Silence Therapeutics PLC Sponsored ADR stock logo
SLN
Silence Therapeutics
$27.17M6.20N/AN/A$4.48 per share1.26
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Amryt Pharma plc stock logo
AMYT
Amryt Pharma
$1M-$0.06N/A735.00N/A-8.19%1.70%0.75%N/A
IGC Pharma, Inc. stock logo
IGC
IGC Pharma
-$13M-$0.08N/AN/AN/A-714.16%-122.44%-88.40%N/A
Organon & Co. stock logo
OGN
Organon & Co.
$864M$2.693.492.510.9411.15%163.88%6.99%10/30/2025 (Estimated)
Silence Therapeutics PLC Sponsored ADR stock logo
SLN
Silence Therapeutics
-$45.31M-$1.65N/AN/AN/A-294.20%-67.48%-40.47%8/21/2025 (Estimated)

Latest IGC, SLN, AMYT, and OGN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/21/2025Q2 2025
Silence Therapeutics PLC Sponsored ADR stock logo
SLN
Silence Therapeutics
-$0.2067N/AN/AN/A$3.38 millionN/A
8/7/2025Q2 2025
Silence Therapeutics PLC Sponsored ADR stock logo
SLN
Silence Therapeutics
-$0.27-$0.54-$0.27-$0.57$8.50 million$0.22 million
8/5/2025Q2 2025
Organon & Co. stock logo
OGN
Organon & Co.
$0.94$1.00+$0.06$0.56$1.55 billion$1.59 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Amryt Pharma plc stock logo
AMYT
Amryt Pharma
N/AN/AN/AN/AN/A
IGC Pharma, Inc. stock logo
IGC
IGC Pharma
N/AN/AN/AN/AN/A
Organon & Co. stock logo
OGN
Organon & Co.
$0.080.85%N/A2.97%N/A
Silence Therapeutics PLC Sponsored ADR stock logo
SLN
Silence Therapeutics
N/AN/AN/AN/AN/A

Latest IGC, SLN, AMYT, and OGN Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
8/6/2025
Organon & Co. stock logo
OGN
Organon & Co.
quarterly$0.020.9%8/15/20258/15/20259/11/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Amryt Pharma plc stock logo
AMYT
Amryt Pharma
0.64
1.57
0.94
IGC Pharma, Inc. stock logo
IGC
IGC Pharma
0.02
1.15
0.98
Organon & Co. stock logo
OGN
Organon & Co.
11.98
1.65
1.13
Silence Therapeutics PLC Sponsored ADR stock logo
SLN
Silence Therapeutics
N/A
10.06
10.06

Institutional Ownership

CompanyInstitutional Ownership
Amryt Pharma plc stock logo
AMYT
Amryt Pharma
71.31%
IGC Pharma, Inc. stock logo
IGC
IGC Pharma
3.87%
Organon & Co. stock logo
OGN
Organon & Co.
77.43%
Silence Therapeutics PLC Sponsored ADR stock logo
SLN
Silence Therapeutics
98.73%

Insider Ownership

CompanyInsider Ownership
Amryt Pharma plc stock logo
AMYT
Amryt Pharma
5.66%
IGC Pharma, Inc. stock logo
IGC
IGC Pharma
31.48%
Organon & Co. stock logo
OGN
Organon & Co.
1.96%
Silence Therapeutics PLC Sponsored ADR stock logo
SLN
Silence Therapeutics
4.10%
CompanyEmployeesShares OutstandingFree FloatOptionable
Amryt Pharma plc stock logo
AMYT
Amryt Pharma
2,02063.96 million60.34 millionNot Optionable
IGC Pharma, Inc. stock logo
IGC
IGC Pharma
6190.81 million54.60 millionN/A
Organon & Co. stock logo
OGN
Organon & Co.
4,000259.97 million254.87 millionNot Optionable
Silence Therapeutics PLC Sponsored ADR stock logo
SLN
Silence Therapeutics
10029.93 millionN/ANot Optionable

Recent News About These Companies

William Blair Issues Pessimistic Forecast for SLN Earnings
Silence Therapeutics' (SLN) "Buy" Rating Reiterated at Chardan Capital
Silence Therapeutics plc GAAP EPS of -C$0.20
Silence Therapeutics initiated with a Sell at Goldman Sachs
Goldman starts Silence Therapeutics at Sell on ‘undifferentiated’ data

New MarketBeat Followers Over Time

Media Sentiment Over Time

Amryt Pharma stock logo

Amryt Pharma NASDAQ:AMYT

Amryt Pharma plc, a commercial-stage biopharmaceutical company, focuses on acquiring, developing, and commercializing various treatments to help improve the lives of patients with rare and orphan diseases. The company provides metreleptin, an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy; oral octreotide, a long-term maintenance therapy in acromegaly patients; and lomitapide, an adjunct to a low-fat diet and other lipid-lowering medicinal products for adults with the Homozygous familial Hypercholesteraemia. Its development candidates include Oleogel-S10 for the cutaneous manifestations of Junctional and Dystrophic Epidermolysis Bullosa (EB), a rare and distressing genetic skin disorder affecting young children and adults; and AP103, a pre-clinical gene therapy for patients with dystrophic EB. The company sells its products in the Americas, Europe, and the Middle East. Amryt Pharma plc was founded in 2015 and is headquartered in Dublin, Ireland.

IGC Pharma stock logo

IGC Pharma NYSEMKT:IGC

$0.36 +0.03 (+9.78%)
Closing price 03:59 PM Eastern
Extended Trading
$0.36 +0.00 (+0.56%)
As of 06:25 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

IGC Pharma, Inc., a clinical stage pharmaceutical company, engages in developing treatments for Alzheimer's disease. The company's lead product is IGC-AD1, which is in a Phase 2B clinical trial as a treatment for agitation in dementia due to Alzheimer's; and TGR-63, IGC-1C, IGC-M3, and LMP in pre-clinical development. The company was formerly known as India Globalization Capital, Inc. and changed its name to IGC Pharma, Inc. in March 2023. The company was incorporated in 2005 and is headquartered in Potomac, Maryland.

Organon & Co. stock logo

Organon & Co. NYSE:OGN

$9.38 +0.03 (+0.27%)
Closing price 03:59 PM Eastern
Extended Trading
$9.39 +0.01 (+0.05%)
As of 06:12 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.

Silence Therapeutics stock logo

Silence Therapeutics NASDAQ:SLN

$5.63 -0.22 (-3.76%)
Closing price 04:00 PM Eastern
Extended Trading
$5.61 -0.02 (-0.36%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver. The company develops Zerlasiran (SLN360), which is in phase 2 clinical trial for cardiovascular disease associated with elevated lipoprotein(a); and Divesiran (SLN124), an siRNA molecule that is in Phase I clinical trials for the treatment of genetic hematological conditions, including polycythemia vera. It is also developing SLN-COMP-1 and SLN-COMP-2 for complement-mediated diseases; and SLN-HAN-1 and SLN-HAN-2. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; Hansoh Pharmaceutical Group Company Limited to develop siRNAs; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, the United Kingdom.